CDMO Catalent’s UpTempo℠ adeno-associated viral (AAV) platform process accelerates time from gene to clinic.
Catalent’s UpTempo℠ adeno-associated viral (AAV) platform process accelerates the development and production of clinical material for gene therapy. With a simplified supply chain, increased development and manufacturing efficiencies, and standardized documentation, this scalable, cGMP-ready platform process can significantly reduce the time from gene to clinic. With viral vector and plasmid DNA development and clinical- and commercial-scale manufacturing facilities in its global network, Catalent offers horizontally integrated solutions to support advanced therapy programs.
Link: https://biologics.catalent.com/gene-therapy/process-development/aav-platform-process/
Visit booth 229 to meet with Catalent’s cell and gene therapy experts and learn more about the company’s integrated solutions for advanced therapeutics.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.